DocMeetings

Join us at the Dermatology Innovation Leadership Think Tank meeting featuring Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.

The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.

Webinar Takeaways:

• Understand how chimeric antigen receptor technology harnesses the immune system’s power to induce lasting remissions of previously refractory B cell leukemias and lymphomas.
• See how breakthrough discoveries in B cell-mediated cancers have led to innovative approaches for B cell-mediated autoimmune diseases that may offer similar potential for lasting remission.
• Learn how novel CAR technologies can provide opportunity to impactfully treat and potentially cure a breadth of gamma-delta T cell leukemias and lymphomas.